Synergy Pharma Cmn (SGYP) 4.11 $SGYP Synergy

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Synergy Pharma Cmn (SGYP) 4.11 $SGYP

Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - 2 hrs 3 mins ago
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 4.11 (+0.03)

Herbalife and Ironwood advance; Infosys and Fairmount drop
AP - Fri Jul 15, 3:11PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
SGYP: 4.11 (+0.03), HLF: 67.30 (-0.71), FMSA: 6.39 (-0.46), IRWD: 14.25 (+0.12), CCL: 46.59 (-0.13), C: 43.75 (-0.06), WFC: 47.87 (-0.10), INFY: 16.56 (+0.13)

Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
BusinessWire - Fri Jul 15, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Additionally, the company is providing an update on the ongoing irritable bowel syndrome with constipation (IBS-C) program.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 4.11 (+0.03)

Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)

Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What:  After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals  were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)

These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 4.11 (+0.03)

Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 4.11 (+0.03), DB: 13.17 (-0.27)

Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 4.11 (+0.03), IRWD: 14.25 (+0.12)

What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What:  After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.11 (+0.03), HRTX: 18.56 (+1.94), RPRX: 2.05 (-0.07)

Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
BusinessWire - Tue Apr 19, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company's New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
SGYP: 4.11 (+0.03)

Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 4.11 (+0.03), CANF: 2.11 (+0.01), OMEX: 2.93 (-0.02), MNKD: 1.00 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 92

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 155

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 178

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 239

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Vivid Seats Simplifies Market Structure and Tax Obligations

Updated Category News Views 221

Vivid Seats Streamlines Corporate Structure Vivid Seats Inc. (NASDAQ: SEAT), a leading online ticket marketplace, has embarked on a transformative journey to simplify its organizational framework. In a strategic move, the company has announced its Corporate Simplification Agreement, aimed at redefining how it operates while enhancing its tax efficiency and overall...

Continue Reading
NLS Pharmaceuticals Soars After Major Merger Announcement

Updated Category News Views 330

NLS Pharmaceuticals Sees Positive Stock Movement NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) is experiencing significant upward momentum in its stock prices following a crucial announcement regarding a proposed merger. The company has filed a Form F-4 registration statement with the Securities and Exchange Commission, signaling an essential step toward completing this merger....

Continue Reading
Orchestra BioMed Achieves Key Financial and Operational Progress

Updated Category News Views 84

Orchestra BioMed Reports on Financial Performance and Business Updates Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), a pioneering biomedical innovation company, recently presented its robust financial results for Q3 2024, reflecting both significant fiscal health and promising advancements in medical technology. The company is focused on elevating patient care through...

Continue Reading
Nutex Health Inc. Investors Urged to Join Securities Class Action

Updated Category News Views 130

Investors of Nutex Health Inc. Face Opportunities Amid Allegations Investors holding shares in Nutex Health Inc. are currently presented with a remarkable opportunity in light of claims surrounding securities fraud involving the Company. Founded as a notable player in the healthcare sector, Nutex Health has recently come under scrutiny due to alleged misleading statements...

Continue Reading
Empowering Resilience in Education: Embracing Failure with LetMeFail

Updated Category News Views 182

Transforming Education: LetMeFail's Innovative Approach LetMeFail is an exciting new educational initiative aimed at transforming how students perceive and deal with failure. In today's culture, where perfection is often idolized, this program makes it clear that setbacks can serve as important stepping stones toward personal growth and resilience. Unpacking the Goals of...

Continue Reading